IDXX — IDEXX Laboratories Income Statement
0.000.00%
Last trade - 00:00
- $44.10bn
- $44.59bn
- $3.66bn
- 99
- 10
- 89
- 72
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 2,407 | 2,707 | 3,215 | 3,367 | 3,661 |
Cost of Revenue | |||||
Gross Profit | 1,366 | 1,571 | 1,889 | 2,004 | 2,190 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Total Operating Expenses | 1,854 | 2,012 | 2,283 | 2,469 | 2,564 |
Operating Profit | 553 | 695 | 932 | 899 | 1,097 |
Total Net Non Operating Interest Income / Expense | |||||
Net Income Before Taxes | 522 | 662 | 903 | 860 | 1,061 |
Provision for Income Taxes | |||||
Net Income After Taxes | 428 | 582 | 745 | 679 | 845 |
Minority Interest | |||||
Net Income Before Extraordinary Items | |||||
Net Income | 428 | 582 | 745 | 679 | 845 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | 428 | 582 | 745 | 679 | 845 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | 4.89 | 6.73 | 8.65 | 8.03 | 10.1 |